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Background: There is growing evidence that nutritional interventions in the first 1,000 days of life may 33 
influence long-term health and development outcomes. Few studies have examined the effect of maternal 34 
and infant micronutrient supplementation on development outcomes in sub-Saharan Africa.  35 
Methods: We conducted a follow-up study of two randomized trials of antenatal and infant micronutrient 36 
supplementation conducted in Dar es Salaam, Tanzania.  We assessed the effect of maternal multiple 37 
micronutrient (MMN) supplementation in pregnancy on development of children at 11-14 years of age.  38 
We also examined the effect of infant zinc and MMN supplementation on development at 6-8 years of 39 
age. We use generalized linear models to assess standardized mean differences (SMDs) in general 40 
intelligence, executive function and mental health scores.  41 
Results: We followed-up 446 children whose mothers were enrolled in the maternal MMN 42 
supplementation trial and 365 children who were enrolled in the infant zinc and MMN supplementation 43 
trial. We found no effect of maternal MMN supplementation on general intelligence (SMD: -0.03; 95% 44 
CI: -0.15, 0.09), executive function (SMD: 0.00; 95% CI: -0.11, 0.11) and mental health scores (SMD: 45 
0.06; 95% CI: -0.10, 0.22).  We also found no effect of either infant zinc or MMN supplementation on 46 
any of the three development domains (p-values >0.05).   47 
Conclusions: We found that antenatal MMN supplementation and infant zinc and MMN supplementation 48 
did not have a large effect on development outcomes in middle childhood and early adolescence in 49 










 It is estimated that 250 million children under the age of 5 years in low- and middle-income 58 
countries (LMICs) do not currently reach their full developmental potential (1). Suboptimal cognitive, 59 
language, motor and socioemotional development in LMICs is likely related to a combination of poverty-60 
related biological, environmental, and psychosocial exposures (2).  Developmental deficits during early 61 
childhood may persist and have a range of consequences across the life course including poor schooling 62 
achievement and reductions in lifetime earnings (3, 4). Therefore, interventions that promote early child 63 
development in LMICs may produce significant individual and societal benefit.  64 
 The first 1,000 days of life (conception through 2 years of age) represents a critical window of 65 
child growth and brain development.  There is a relatively large body of observational evidence linking 66 
low birth weight and linear growth faltering with suboptimal cognitive and motor development (2, 5). 67 
Observational studies have also linked nutritional intake and status during pregnancy with early childhood 68 
with later developmental outcomes (6, 7). However, evidence on the effect of nutrition interventions 69 
during the first 1,000 days of life on short- and long-term development outcomes in LMICs is much more 70 
limited. Long-term follow-up studies of randomized trials of prenatal (maternal) multiple micronutrient 71 
(MMN) supplements in pregnancy conducted in Indonesia, China, and Nepal have noted null or mixed 72 
effects on development outcomes in middle childhood and early adolescence; however, there is some 73 
indication that MMN may provide greater benefits for girls and children born to mothers who were 74 
anemic in pregnancy (8-11). As for post-natal (infant) micronutrient supplementation, the most recent 75 
Cochrane Review on zinc supplementation, that included no trials from sub-Saharan Africa, found no 76 
effect on mental and psychomotor development scores (12). As a result, the evidence on the effect of 77 
maternal and infant micronutrient supplementation on development outcomes is mixed and is particularly 78 
limited in the population of mothers and infants in sub-Saharan Africa.  79 
 We present a long-term follow-up study of two randomized trials of maternal and child 80 
micronutrient supplementation conducted in Dar es Salaam, Tanzania.  The first trial randomized HIV-81 
uninfected pregnant women to daily MMN supplementation or placebo; we assessed development 82 
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outcomes of their children at 11-14 years of age (13). The second trial examined the effect of child zinc 83 
and MMN supplementation among HIV-uninfected infants; we followed-up these children at 6-8 years of 84 
age (14). In this report we examined the effect of the randomized supplementation regimens in each trial 85 
on general intelligence, executive function and on instruments reflecting mental health. 86 
  87 
Materials and Methods 88 
Study Population 89 
The protocol for this long-term child development follow-up study has been fully detailed 90 
elsewhere (15). Briefly, we enrolled children from two randomized, double-blind trials of micronutrient 91 
supplementation conducted in Dar es Salaam, Tanzania: 1) a trial of maternal MMN supplementation in 92 
pregnancy (NCT00197548) and 2) a trial of infant zinc and MMN supplementation (NCT00197548) (13, 93 
14).  94 
The maternal multivitamin supplementation trial began enrollment in August 2001 and completed 95 
follow-up for the primary outcomes in February 2005 (13). The trial enrolled 8,428 HIV-uninfected 96 
pregnant women at 12-28 weeks gestation. Pregnant women were randomized to either a daily MMN or 97 
placebo regimen and were supplemented and followed up until 6 weeks postpartum. The MMN 98 
supplements contained 20 mg of vitamin B1, 20 mg of vitamin B2, 25 mg of vitamin B6, 100 mg of 99 
niacin, 50 μg of vitamin B12, 500 mg of vitamin C, 30 mg of vitamin E, and 0.8 mg of folic acid. These 100 
amounts were twice the recommended dietary allowance (RDA) for vitamin E and 6 to nearly 20 times 101 
the RDA for B vitamin complex and vitamin C (16).  All participants received 60 mg iron and 0.25 mg 102 
folic acid (IFA) as standard of care.  103 
The infant micronutrient supplementation trial began enrollment in July 2007 and completed 104 
follow-up for the primary outcomes in May 2011 (14). The trial enrolled 2,400 HIV-unexposed infants at 105 
6 weeks of age and supplemented children to 18 months of age. Infants were randomized in a factorial 106 
design to receive a daily oral dose of one of four trial regimens: 1) zinc, 2) MMN, 3) zinc + MMN, or 4) 107 
placebo.  Infants received one capsule per day from 6 weeks to 6 months of age and then two capsules per 108 
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day from 7 months of age to the end of follow-up at 18 months post-randomization. Infants in the zinc 109 
group received capsules that contained 5 mg of zinc. Infants in the multivitamin group received capsules 110 
that contained 60 mg of vitamin C, 8 mg of vitamin E, 0.5 mg of thiamine, 0.6 mg of riboflavin, 4 mg of 111 
niacin, 0.6 mg of vitamin B-6, 130 mg of folate, and 1 mg of vitamin B12. These doses were between 112 
150% and 600% of the RDA or Adequate Intake (AI) for children 0-6 months of age and 200–400% of 113 
the RDA or AI for infants older than 6 months. 114 
 115 
Child Development Follow-up Procedures and Assessments 116 
The follow-up study was conducted from July 2015 – March 2017. All child participants of the 117 
maternal supplementation and child supplementation trials were eligible for recruitment into the follow-118 
up study. Children of mothers who were enrolled in the maternal multivitamin supplementation trial were 119 
11-14 years of age at the time of the follow-up study, while children enrolled in the infant zinc and 120 
multivitamin supplementation trial were 6-8 years of age.  Written informed consent was sought from 121 
mothers or primary caregivers for all child participants; children were excluded from the study if the 122 
mother or primary caregiver did not consent for participation.   123 
 A full description of the child development test battery used in the follow-up study has been 124 
detailed elsewhere (15, 17). Briefly, we administered the East African Neurodevelopment Tools to 125 
children in both trials (17); the tests included the Atlantis, hand movements, footsteps, story completion, 126 
Kilifi Naming Test, Rey–Osterrieth complex figure (ROCF), go/no go test for sustained attention and 127 
response control (NOGO), shift, people search, literacy and numeracy tests. In addition, the Koh’s Block 128 
Design Test and Verbal Fluency tests were conducted as assessments of general intelligence. We also 129 
administered the Strengths and Difficulties Questionnaire (SDQ) and the Behaviour Rating Inventory of 130 
Executive Function (BRIEF) to assess mental health.  The study staff who administered the development 131 
assessment, the parents, and the children were blinded to their randomized trial group.  132 
We assessed inter-rater reliability of each development test in a subgroup of 18 children by 133 
having two interviewers assess the same child at the same time. We conducted these inter-rater reliability 134 
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tests regularly at one month intervals during the full period of data collection. Kappa coefficients were 135 
used to capture the reliability of responses between interviewers for these 18 children and the results are 136 
presented in Supplemental Table 1.  There was high agreement between interviewers for all tests (kappa 137 
coefficients >0.60), other than the Kilifi naming test (kappa coefficient: 0.42) and verbal fluency (kappa 138 
coefficient: 0.47) which had moderate reliability.  139 
 140 
Statistical Methods 141 
All primary statistical analyses were based on the intention-to-treat principle and were performed 142 
separately by maternal and infant supplementation trial.  The development assessments were first grouped 143 
into three domains: general intelligence (Atlantis, Footsteps, Hand movement, Kilifi naming test, Koh’s 144 
block design test, Story completion, and verbal fluency), executive function (Literacy, Numeracy, NOGO, 145 
People search, ROCF copy, ROCF recall, and Shift), and mental health (BRIEF and SDQ).  Individual 146 
test scores were converted to z-scores and averaged to create a composite z-score for each of the three 147 
domains.  This analytic method was used to reduce the risk of Type I errors due to multiple testing and 148 
has also been used by other studies (11).  Prior to z-score conversion, all test scores were examined for 149 
skewness and those with a skewness value above 1 or below -1 were log-transformed.  If the log-150 
transformation reduced skewness, the log-transformed score was then converted to a z-score.  All scores 151 
for which a lower score indicated a better performance were also multiplied by -1 before z-score 152 
conversion.  All domain scores exceeding 5 standard deviations above or below the median were 153 
excluded from the analysis of the domain.   154 
Generalized linear models with robust variances were used to determine the effect of randomized 155 
regimen on the general intelligence, executive function, and mental health development domain z-scores. 156 
Standardized mean differences (SMDs) and their 95% confidence intervals are presented for each domain. 157 
The primary analytic models were adjusted for child sex, age, and interviewer. As a sensitivity analysis, 158 
we additionally adjusted for sociodemographic characteristics including baseline maternal education, 159 
marital status, parity and household assets due to potential for imbalance by randomized regimen (even if 160 
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not statistically significant) and an independent relationship with development outcomes.  We also 161 
explored whether there was any difference in individual test scores of each domain by randomized 162 
regimen using the non-parametric Kruskal–Wallis test. Due to evidence that the effect of maternal MMN 163 
supplementation in pregnancy on child development scores may be modified by child sex and maternal 164 
anemia status, we also present effect estimates for the maternal supplementation trial stratified by these 165 
variables (9, 11).  In order to examine the risk of selection bias, we also compared characteristics of 166 
children and caregivers that were enrolled in the development follow-up study to those who did not 167 
participate. Missing data for covariates were retained in the analysis using the missing indicator method. 168 
All p-values were 2-sided and a p-value of less than 0.05 was considered statistically significant. 169 
Statistical analyses were performed using the SAS v 9.4 (SAS Institute, Cary, NC). 170 
 171 
Results 172 
A total of 8,428 pregnant women and 2,400 infants were enrolled in the parent maternal and child 173 
micronutrient supplementation trials, respectively.  Figure 1 presents the participant flow for the main 174 
trials and the child development follow-up study.  In the maternal MMN supplementation trial a total of 175 
7,828 infants were alive at the end of the main trial follow-up period at 6 weeks of age; we enrolled 446 176 
children at 11-14 years of age in the follow-up study. In the child zinc and MMN supplementation trial, 177 
2,355 infants were alive at the end of the main trial follow-up at 2 years of age; we enrolled 365 children 178 
at 6-8 years of age in the follow-up study.  We found that baseline characteristics between children 179 
enrolled in the development follow-up study were relatively similar to those who were not enrolled in 180 
both the maternal MMN and infant micronutrient supplementation trials (Supplemental Tables 2 and 3).  181 
Table 1 presents characteristics of child development follow-up study participants stratified by maternal 182 
and child supplementation trial.  We examined potential imbalances in baseline characteristics by 183 
randomized treatment arm in each trial separately and found no indication of major imbalance between 184 




Effect of maternal MMN supplementation on development outcomes 187 
 The effect of maternal MMN supplementation on general intelligence, executive function and 188 
mental health z-scores at 11-14 years old is presented in Table 2. We found no effect of maternal MMN 189 
supplementation on any of the three development domains (p-values >0.05).   In sensitivity analyses we 190 
also found no effect of maternal MMN after multivariate adjustment (Supplemental Table 6) or on 191 
individual test scores within the domains (Supplemental Table 7).  In an exploratory analysis, we 192 
examined the effect of MMN on development outcomes stratified by maternal anemia status at trial 193 
enrollment in pregnancy and by child sex (Supplemental Table 8).  There was some indication, although 194 
not statistically significant, that there may be a greater effect of MMN on mental health among pregnant 195 
women who were anemic at enrollment (SMD: 0.15; 95% CI: -0.07, 0.36) as compared to those who were 196 
not anemic (SMD: 0.06; 95% CI: -0.29, 0.42) (p-value for effect modification: 0.24).  There was no 197 
indication that child sex modified the effect of MMN supplementation on development. 198 
 199 
Effect of infant zinc and MMN supplementation on development outcomes 200 
 In the factorial designed infant supplementation trial, we found no evidence of interaction of 201 
infant zinc and MMN supplementation on the three development domains and therefore we present the 202 
study arms collapsed (p-values for interaction >0.05). We found no effect of infant zinc or MMN 203 
supplementation any development domain at 6-8 years of age (Table 3). We also found no effect of zinc 204 
or MMN supplementation on any development after multivariate adjustment (Supplemental Table 9) or 205 
on individual tests within the three domains (Supplemental Table 10).  206 
  207 
Discussion 208 
 In this long-term follow-up study, we found no significant effect of maternal MMN 209 
supplementation in pregnancy on general intelligence, executive function or mental health of their 210 
children at 11-14 years of age. Similarly, we found no effect of infant zinc and MMN supplementation on 211 
these development domains at 6-8 years of age.  212 
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 We did not identify an effect of maternal MMN supplementation on child development outcomes, 213 
which is in-line with the overall null findings in other follow-up studies (9, 10); however, there is also 214 
some evidence that MMN in pregnancy may provide child development benefits in some populations or 215 
subgroups of children (8, 9, 11).  In a follow-up study conducted in Indonesia, children whose mothers 216 
received antenatal MMN supplementation scored a mean 0.11 standard deviations higher on procedural 217 
memory tests at 9-12 years of age as compared to children of mothers who received iron-folic acid alone 218 
(11). Additionally, this study found that children of anemic pregnant women who received MMN scored 219 
0.18 standard deviations higher on general intelligence tests as compared to children of anemic pregnant 220 
women who received iron-folic acid alone (11).  In our study, we found some indication in study that 221 
MMN may have a greater positive effect on mental health among children born to anemic mothers. This 222 
evidence suggests that MMN may provide greater benefit for mothers who are undernourished in 223 
pregnancy. Another recent study of maternal MMN in Nepal found no overall effect on child IQ at 12 224 
years of age; however, girls whose mothers were randomized to MMN had significantly higher IQ (~3 IQ 225 
points) than girls of mothers who were randomized to iron-folic acid alone (9).  There is also evidence 226 
that MMN supplementation in pregnancy may produce greater survival benefits for female as compared 227 
to male infants (18). As a result, further research on differences in the response to micronutrient 228 
supplementation in pregnancy by maternal nutritional status and sex are needed. 229 
 There are multiple mechanisms by which micronutrient supplements in pregnancy could 230 
influence child development outcomes.  There is evidence that some vitamins and minerals, like vitamin 231 
B12, have a direct effect on brain development and function (19). A recent trial in India determined that 232 
children of mothers who received vitamin B12 supplementation in pregnancy had significantly higher 233 
scores on expressive language scores as compared to children of mothers who received placebo (20). 234 
There are also many indirect pathways through which micronutrients may potentially provide benefit, 235 
including increases in birthweight, reduction in risk of prematurity, and reductions in maternal and fetal 236 
inflammation that may subsequently influence child development (18, 21).  In the primary report of the 237 
maternal supplementation trial, we found that antenatal MMN reduced the risk of low birth weight by 238 
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18%; low birth weight is a well-characterized predictor of suboptimal child cognitive development (13, 239 
22, 23). Therefore, research is needed to determine which components of multivitamins may produce 240 
positive effects and also their mechanisms of action. 241 
 Prophylactic zinc supplementation for infants 6-24 months of age has been shown to reduce 242 
diarrhea incidence (24); however, the effect on child development outcomes remains equivocal (12). 243 
Diarrhea during infancy has been negatively linked with cognitive development; however, the effect for 244 
each additional diarrhea episode is suspected to be small (SMD <0.10) (25, 26). In the parent trial, we 245 
determined that infant zinc supplementation starting at 6 weeks of age reduced the risk of diarrhea during 246 
the 18-month follow-up period; however, in this follow-up study we found no significant effect on 247 
development outcomes at 6-8 years of age (14). The most recent Cochrane review determined there was 248 
no effect of infant zinc supplementation on mental development index (MDI) and psychomotor 249 
development index (PDI) scores of the Bayley Scales of Infant Development, although due to the small 250 
sample size the uncertainty in the estimates was large (12).  As a result, larger studies of prophylactic zinc 251 
supplementation and child development will be needed to identify an effect size that may be 0.10 SD or 252 
less. 253 
 There is sparse evidence on the effect of infant MMN supplementation on development 254 
outcomes. The most recent meta-analysis identified six infant MMN trials that suggested there may be 255 
potential for benefit on mental development (SMD: 0.08; 95% CI: -0.01, 0.18), but the results were not 256 
statistically significant (27). Nevertheless, there is growing evidence that infant vitamin B12 257 
supplementation, which was a component of our MMN supplements, may produce positive cognitive and 258 
motor effects.  A recent randomized controlled trial of vitamin B12 and folic acid supplementation among 259 
Indian children aged 6–30 months found that children provided with both vitamin B12 and folic acid had 260 
better gross motor and problem solving functioning as compared to those who received placebo (27, 28). 261 
Overall, there are significant research gaps on the role of individual and combined micronutrient 262 
supplementation in development of infants and children.  263 
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 There are a few limitations of this study. Foremost, we were only able to enroll 5% of the 264 
maternal supplementation trial cohort and 15% of the infant supplementation trial cohort and therefore 265 
our study is at risk of bias due to loss to follow-up. Although the measured baseline characteristics of 266 
study participants who were enrolled in the development follow-up study tended to be similar to 267 
participants who were not enrolled, we cannot empirically rule out the potential for selection bias.  In 268 
addition, due to the small sample size of the follow-up study cohorts, we had limited power (<20%) to 269 
detect differences in child development that are likely for nutritional interventions in pregnancy and 270 
infancy (~0.1 standard deviations) (27). In addition, the full battery of development assessments used in 271 
our study has also not been directly validated for children in Tanzania and therefore there is a risk of non-272 
differential misclassification for individual test and domain scores that would bias estimates to the null. 273 
As a result, studies examining the effect on objective measures of neuroanatomy and neurologic function 274 
may produce different results (29, 30).  275 
 We found that antenatal MMN supplementation and infant zinc and MMN supplementation did 276 
not have a large effect on general intelligence, executive function and mental health among Tanzanian 277 
children in middle childhood and early adolescence; however, we cannot rule out small to moderate 278 
beneficial or harmful effect.  Integrated nutrition, environmental and stimulation interventions may 279 





We would like to thank Muhimbili University of Health and Allied Sciences for their continued 285 
support of our research and for allocating special space for the development assessments. We also thank 286 
Melba Golmes, Charles Makasi and the East African Development Tool team for allowing us to use 287 
components of the tool and Hadija Nangaboi for leading the training on these assessments. We also thank 288 
Dr. Srinivasan Krishnamachari and his team at St. John’s Research Institute for guidance and training on 289 
the Verbal Fluency and Kohs Block Design Test.  We thank the Research Assistants at MUHAS 290 
12 
 
including Sr. Juliana Mghamba, Sr. Agnes Obedi, Sr. Anna Fundi, Sr. Celestina Kagunila and Sr. 291 
Veneranda Ndesangia and sociologists Alice Mabugo and Leah Sabasi. We also thank Mohamed Bakari 292 
for developing and maintaining the data system for the study. Finally, we thank the parents and children 293 
for their continued participation in the two trials.  294 
 295 
Conflict of Interest 296 
The authors declare no conflict of interest. 297 
 298 
 299 
Author Contributions 300 
WWF, CPD and KPM were the Principal Investigators of the parent trials. WWF, CPD, KPM, and RK 301 
contributed to conduct of the parent trials.  TAS, IK, MH WWF, CPD and KPM designed the 302 
development follow-up study and obtained funding. KPM, RK, IK, MH, DCM, TAS, CPD, and WWF 303 
were involved in the adaptation and training of the development tool assessments used in the follow-up 304 
study. KPM and RK led field implementation of the follow-up study. CRS and AMD conducted the 305 
statistical analysis. CRS drafted the initial manuscript. All authors made significant contributions to 306 
editing the manuscript and all approved of the final manuscript for submission.  307 
 308 
Funding 309 
The development follow-up study was funded by the Norwegian Research Council Grant number 234495. 310 
The parent randomized trials were funded by the Eunice Kennedy Shriver National Institute of Child 311 
Health & Human Development (NICHD) (R01 37701 and R01 HD048969-01). CPD was supported by 312 
K24DK104676 and P30 DK040561. 313 
 314 
Supplementary Information 315 




1. Lu C, Black MM, Richter LM. Risk of poor development in young children in low-income and 
middle-income countries: an estimation and analysis at the global, regional, and country level. Lancet 
Glob Health. 2016;4(12):e916-e22. 
2. Black MM, Walker SP, Fernald LCH, Andersen CT, DiGirolamo AM, Lu C, et al. Early childhood 
development coming of age: science through the life course. Lancet. 2017;389(10064):77-90. 
3. Fink G, Peet E, Danaei G, Andrews K, McCoy DC, Sudfeld CR, et al. Schooling and wage income 
losses due to early-childhood growth faltering in developing countries: national, regional, and global 
estimates. Am J Clin Nutr. 2016;104(1):104-12. 
4. Peet ED, McCoy DC, Danaei G, Ezzati M, Fawzi W, Jarvelin MR, et al. Early Childhood 
Development and Schooling Attainment: Longitudinal Evidence from British, Finnish and Philippine Birth 
Cohorts. PLoS One. 2015;10(9):e0137219. 
5. Sudfeld CR, McCoy DC, Danaei G, Fink G, Ezzati M, Andrews KG, et al. Linear growth and child 
development in low- and middle-income countries: a meta-analysis. Pediatrics. 2015;135(5):e1266-75. 
6. Veena SR, Gale CR, Krishnaveni GV, Kehoe SH, Srinivasan K, Fall CH. Association between 
maternal nutritional status in pregnancy and offspring cognitive function during childhood and 
adolescence; a systematic review. BMC pregnancy and childbirth. 2016;16:220. 
7. Borge TC, Aase H, Brantsaeter AL, Biele G. The importance of maternal diet quality during 
pregnancy on cognitive and behavioural outcomes in children: a systematic review and meta-analysis. 
BMJ open. 2017;7(9):e016777. 
8. Zhu Z, Cheng Y, Zeng L, Elhoumed M, He G, Li W, et al. Association of Antenatal Micronutrient 
Supplementation With Adolescent Intellectual Development in Rural Western China: 14-Year Follow-up 
From a Randomized Clinical Trial. JAMA Pediatr. 2018;172(9):832-41. 
9. Dulal S, Liegeois F, Osrin D, Kuczynski A, Manandhar DS, Shrestha BP, et al. Does antenatal 
micronutrient supplementation improve children's cognitive function? Evidence from the follow-up of a 
double-blind randomised controlled trial in Nepal. Lancet Glob Health. 2018;3(1):e000527. 
10. Christian P, Murray-Kolb LE, Khatry SK, Katz J, Schaefer BA, Cole PM, et al. Prenatal 
micronutrient supplementation and intellectual and motor function in early school-aged children in 
Nepal. Jama. 2010;304(24):2716-23. 
11. Prado EL, Sebayang SK, Apriatni M, Adawiyah SR, Hidayati N, Islamiyah A, et al. Maternal 
multiple micronutrient supplementation and other biomedical and socioenvironmental influences on 
children's cognition at age 9-12 years in Indonesia: follow-up of the SUMMIT randomised trial. Lancet 
Glob Health. 2017;5(2):e217-e28. 
12. Gogia S, Sachdev HS. Zinc supplementation for mental and motor development in children. 
Cochrane Database Syst Rev. 2012;12:Cd007991. 
13. Fawzi WW, Msamanga GI, Urassa W, Hertzmark E, Petraro P, Willett WC, et al. Vitamins and 
perinatal outcomes among HIV-negative women in Tanzania. N Engl J Med. 2007;356(14):1423-31. 
14. McDonald CM, Manji KP, Kisenge R, Aboud S, Spiegelman D, Fawzi WW, et al. Daily Zinc but Not 
Multivitamin Supplementation Reduces Diarrhea and Upper Respiratory Infections in Tanzanian Infants: 
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. J Nutr. 2015;145(9):2153-60. 
15. Winje BA, Kvestad I, Krishnamachari S, Manji K, Taneja S, Bellinger DC, et al. Does early vitamin 
B12 supplementation improve neurodevelopment and cognitive function in childhood and into school 
age: a study protocol for extended follow-ups from randomised controlled trials in India and Tanzania. 
BMJ Open. 2018;8(2):e018962. 
16. Institute of Medicine Standing Committee on the Scientific Evaluation of Dietary Reference 
Intakes. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, 
pantothenic acid, biotin, and choline. Washington, DC: National Academies Press (US); 1998. 
14 
 
17. Holding P, Anum A, van de Vijver FJR, Vokhiwa M, Bugase N, Hossen T, et al. Can we measure 
cognitive constructs consistently within and across cultures? Evidence from a test battery in Bangladesh, 
Ghana, and Tanzania. Appl Neuropsychol Child 2018;7(1):1-13. 
18. Smith ER, Shankar AH, Wu LS, Aboud S, Adu-Afarwuah S, Ali H, et al. Modifiers of the effect of 
maternal multiple micronutrient supplementation on stillbirth, birth outcomes, and infant mortality: a 
meta-analysis of individual patient data from 17 randomised trials in low-income and middle-income 
countries. The Lancet Global Health. 2017;5(11):e1090-e100. 
19. Black MM. Effects of vitamin B12 and folate deficiency on brain development in children. Food 
Nutr Bull. 2008;29(2 Suppl):S126-31. 
20. Thomas S, Thomas T, Bosch RJ, Ramthal A, Bellinger DC, Kurpad AV, et al. Effect of Maternal 
Vitamin B12 Supplementation on Cognitive Outcomes in South Indian Children: A Randomized 
Controlled Clinical Trial. Matern Child Health J. 2018. 
21. Romero R, Chaiworapongsa T, Espinoza J. Micronutrients and intrauterine infection, preterm 
birth and the fetal inflammatory response syndrome. J Nutr. 2003;133(5):1668S-73S. 
22. Shenkin SD, Starr JM, Deary IJ. Birth weight and cognitive ability in childhood: a systematic 
review. Psychol Bull. 2004;130(6):989-1013. 
23. Twilhaar ES, Wade RM, de Kieviet JF, van Goudoever JB, van Elburg RM, Oosterlaan J. Cognitive 
Outcomes of Children Born Extremely or Very Preterm Since the 1990s and Associated Risk Factors: A 
Meta-analysis and Meta-regression. JAMA Pediatr. 2018;172(4):361-7. 
24. Mayo-Wilson E, Junior JA, Imdad A, Dean S, Chan XH, Chan ES, et al. Zinc supplementation for 
preventing mortality, morbidity, and growth failure in children aged 6 months to 12 years of age. 
Cochrane Database Syst Rev. 2014(5):Cd009384. 
25. Niehaus MD, Moore SR, Patrick PD, Derr LL, Lorntz B, Lima AA, et al. Early childhood diarrhea is 
associated with diminished cognitive function 4 to 7 years later in children in a northeast Brazilian 
shantytown. Am J Trop Med Hyg. 2002;66(5):590-3. 
26. Walker CLF, Lamberti L, Adair L, Guerrant RL, Lescano AG, Martorell R, et al. Does childhood 
diarrhea influence cognition beyond the diarrhea-stunting pathway? PLoS One. 2012;7(10):e47908. 
27. Larson LM, Yousafzai AK. A meta-analysis of nutrition interventions on mental development of 
children under-two in low-and middle-income countries. Matern Child Nutr. 2017;13(1). 
28. Kvestad I, Taneja S, Kumar T, Hysing M, Refsum H, Yajnik CS, et al. Vitamin B12 and Folic Acid 
Improve Gross Motor and Problem-Solving Skills in Young North Indian Children: A Randomized Placebo-
Controlled Trial. PloS one. 2015;10(6):e0129915. 
29. Hajcak G, MacNamara A, Olvet DM. Event-related potentials, emotion, and emotion regulation: 
an integrative review. Dev Neuropsychol,. 2010;35(2):129-55. 
30. Duncan CC, Barry RJ, Connolly JF, Fischer C, Michie PT, Naatanen R, et al. Event-related 
potentials in clinical research: guidelines for eliciting, recording, and quantifying mismatch negativity, 











Table 1. Maternal and child characteristics of development follow-up study participants for the maternal 









Baseline maternal and socioeconomic  characteristics   
Age, years    
          < 20  22 (4.9) 13 (3.6) 
          20 – 24   106 (23.8) 88 (24.4) 
          25 – 29  181 (40.6) 129 (35.7) 
          ≥ 30  137 (30.7) 131 (36.3) 
Education, years    
          None / did not complete primary 37 (8.1) 6 (1.7) 
          Primary  298 (63.2) 238 (65.8)  
          Secondary  106 (22.0) 99 (27.4) 
          Post-secondary 30 (6.7) 19 (5.2)  
Married or living with partner 409 (91.7) 331 (91.7) 
Prior pregnancies   
          None  49 (11.0) 97 (26.7) 
          1 – 4  375 (84.1) 256 (70.5) 
         ≥ 4 22 (4.9) 10 (2.8) 
Household possessions1   
     None  17 (3.8) 134 (37.0) 
     1 - 3 257 (57.6) 196 (54.1) 
     ≥ 4  172 (38.6) 32  (8.8) 
Child characteristics    
     Age at development assessment   
          6-8 0 (0) 365 (100.0) 
          11-14 446 (100.0) 0 (0) 
     Sex    
          Male  226 (50.7) 191 (52.3) 
          Female  220 (49.3) 174 (47.7) 
     Low birth weight (<2500g) 27 (6.1) 6 (1.6) 
     Preterm (<37 weeks gestation) 67 (15.1) 34 (10.6) 
 
1From a list that included a sofa, television, radio, refrigerator, and fan 
 Table 2. Effect of maternal multivitamin supplementation on general intelligence, executive function and 










SMD* (95% CI) 
p-value 
Executive 
function         
z-score (SD) 
Executive 
function           





SMD* (95% CI) p-value 
Placebo                  
[n=237] 
0.00 (0.65) Ref.  0.00 (0.60) Ref.  -0.02 (0.87) Ref.  
Multivitamins                    
[n=209] -0.01 (0.66) 
-0.03                  
(-0.15, 0.09) 0.63 0.00 (0.58) 
0.00                     
(-0.11, 0.11) 0.97 0.02 (0.89) 
0.06                    
(-0.09, 0.22) 0.45 
 
SMD = standardized mean difference 
*Adjusted for child sex, age, and child development assessor 
 
 
Table 3. Effect of infant zinc and multivitamin supplementation on general intelligence, executive 








SMD* (95% CI) 
p-value 
Executive 
function         
z-score (SD) 
Executive 
function           





SMD* (95% CI) p-value 
No zinc                  
[n=198] 
0.00 (0.58) Ref.  0.00 (0.59) Ref.  -0.04 (0.90) Ref.  
Zinc                    
[n=167] 
-0.01 (0.63) 0.02                  
(-0.09, 0.14) 
0.71 0.00 (0.67) 0.03                     
(-0.10, 0.15) 
0.69 0.04 (0.78) 0.02                    
(-0.14, 0.19) 
0.54 
No multivitamins                    
[n=193] 
0.00 (0.61) Ref.  0.00 (0.51) Ref.  -0.04 (0.78) Ref.  
Multivitamins 
[n=172] 
0.00 (0.59) 0.04                  
(-0.07, 0.16) 
0.46 0.00 (0.64) 0.00                     
(-0.12, 0.13) 




SMD = standardized mean difference 


























Figure 1. Flow chart of participation in child development follow-up study for maternal supplementation 
and child supplementation trial cohorts 
 
Figure 1 Footnote. Maternal supplementation trial randomized pregnant women to receive multivitamins 
or placebo supplements from the second trimester of pregnancy to six week postpartum. Infant 
supplementation trial randomized infants to receive multivitamins and zinc, zinc only, multivitamins only, 
or placebo supplements from 6 weeks to 18 months of age.  
 
Test  Kappa (95% CI) 
Atlantis  1.00 (1.00, 1.00) 
Footsteps 0.91 (0.83, 0.98) 
Hand movements 0.87 (0.70, 1.00) 
Kilifi naming test 0.42 (0.21, 0.64) 
Koh’s block design test 0.58 (0.36, 0.81) 
Literacy 0.87 (0.70, 1.00) 
Go/no go test for sustained attention and 
response control (NOGO) 
1.00 (1.00, 1.00) 
Numeracy 0.86 (0.68, 1.00) 
People search  0.76 (0.56, 0.96) 
Rey–Osterrieth complex figure copy 0.81 (0.61, 1.00) 
Rey–Osterrieth complex figure recall  0.88 (0.72, 1.00) 
Shift 0.88 (0.72, 1.00) 
Story completion  0.94 (0.82, 1.00) 
Verbal fluency 0.47 (0.23, 0.71) 
